Suchergebnisse
Relmada Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Relmada Therapeutics, Inc.? Here are five stocks we like better.
- NDV-01 manufacturing is Relmada’s immediate priority as it targets an investigational new drug
Does Patterson-UTI (PTEN) Have the Potential to Rally 37.91% as Wall Street Analysts Expect?
Patterson-UTI (PTEN) closed the last trading session at $10.05, gaining 6.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts See a 34.93% Upside in Trimble (TRMB): Can the Stock Really Move This High?
Trimble Navigation (TRMB) closed the last trading session at $58.55, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
How Much Upside is Left in Gibraltar Industries (ROCK)? Wall Street Analysts Think 33.12%
Gibraltar Industries (ROCK) closed the last trading session at $50.78, gaining 20.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
Iovance Biotherapeutics (IOVA) closed the last trading session at $6.21, gaining 42.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
APA Q2 Earnings Call Highlights Cost Cuts and Permian Efficiency
APA Corporation APA used its second-quarter 2026 earnings call to emphasize lower capital intensity, higher U.S. oil output and a larger cost-savings target. CEO John Christmann and CFO Ben Rodgers